[Chemotherapy combined with Lipiodol. In vitro study of the kinetics of release of adriamycin].
Intra-arterial injection of lipiodol-adriamycin mixtures are commonly used in the treatment of hepatic tumors based on the progressive release of adriamycin. This study was undertaken to assess, in vitro, the influence of mixture formulations on the adriamycin release pattern. Eight mixtures containing 10 mg of adriamycin were tested. Adriamycin was tested in solution (mixture A) in suspension (mixture B), or in emulsions with Hexabrix 320 (mixtures C to F). Ratios between Hexabrix and lipiodol volumes were 2/1, 1/1, 1/2, and 1/4 for emulsions C, D, E, and F, respectively. Emulsions G and H corresponded to emulsions E and F, with Arlacel A as emulsifying agent. All mixtures were prepared in triplicate and added with water. Samples of 200 microliters were taken from the aqueous phase after 10, 20, 30 min, 1, 2, 4, 8, 24, 48, 72, and 120 h for adriamycin dosage. Lipiodol-adriamycin mixture formulation significantly influenced the release pattern of adriamycin. Three formulations (suspension, emulsions 2/1 and 1/4) induced the most progressive release of adriamycin from lipiodol. This release was dramatically retarded by the addition of an emulsifying agent.
Heresbach
D
D
Service d'Hépato-Gastroentérologie, CHU Pontchaillou, Rennes.
Raoul
J L
JL
Bentue-Ferrer
D
D
Bretagne
J F
JF
Van den Driessche
J
J
Gastard
J
J
D003692:Delayed-Action Preparations; D004317:Doxorubicin / Q000493:pharmacokinetics*; D004655:Emulsions; D066298:In Vitro Techniques; D007459:Iodized Oil / Q000493:pharmacokinetics*; D008954:Models, Biological; D012996:Solutions; D013535:Suspensions; D013997:Time Factors
D003692:Delayed-Action Preparations; D004655:Emulsions; D012996:Solutions; D013535:Suspensions; D007459:Iodized Oil; D004317:Doxorubicin
Chimiothérapie couplée au Lipiodol. Etude in vitro de la cinétique de libération de l'adriamycine.